Market News AIOpen the app

Eli Lilly is sharing new trial results for its heart and weight loss products at ObesityWeek 2026.

TrialRead the original at prnewswire.com
Good for LLY

Eli Lilly reported trial findings showing less knee pain, lower BMI in adolescents, and weight loss with better blood sugar. These results support its treatments in development, though EloraTZP is still being tested.

LLY · Eli Lilly and Company

AI read · Good for LLY

The AI's read

The findings add support for several medicines Lilly is developing for obesity and related illnesses. EloraTZP is still in Phase 2 testing, and the report gives no approval or sales results.

Get alerts for LLY

Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LLY
Free on the App Store and Google Play, or on the web.